What is inter partes review and why does it matter?
By Nicole Longo | March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...
Read More
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
By Mark Grayson | May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...
Read More
Illegal trade barriers discriminate against U.S. innovators
By Jay Taylor | May 2, 2017
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American...
Read More
Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.
By Jay Taylor | April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...
Read More
New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
By Lucy Vereshchagina | April 17, 2017
In an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path) announced the launch of a new...
Read More
PhRMA urges USTR to protect American innovators abroad
By Mark Grayson | February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...
Read More
Fact Check Friday: The truth about biopharmaceutical patents
By Mark Grayson | August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines,...
Read More
Canada’s promise doctrine strikes again
By Mark Grayson | May 26, 2016
In just the last few weeks Canada has once again taken steps to invalidate yet another medicine (Zymar®) by applying the “promise doctrine.” See Allergan Inc. v. Apotex Inc., 2016 FC 344 (April 1,...
Read More
Strong IP is propelling innovation and saving lives
By Mark Grayson | May 5, 2016
Each day, new medicines are being researched and developed that save lives and improve patients’ quality of life. As the global epicenter of life science innovation and technological...
Read More
World IP Day: Celebrating the protections that allow innovation to thrive
By Mark Grayson | April 26, 2016
Today is World Intellectual Property Day, a celebration across the globe of the protections that allow creativity, risk-taking and innovation to thrive. America has long been the world’s innovation...
Read More
Medicare Monday (100)
340B Spotlight (33)
Cost & Consequence (0)
